PCVX · Earnings event · Q2 2026 · archived
Vaxcyte (PCVX) Q2 2026 earnings — TrendMatrix coverage
Reported · EPS $-1.97 vs estimate $-2.10 (+6.1%) — classified BEAT.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Event detail · Q2 2026
EPS beat/miss and revenue
| Metric | Estimate | Actual | Surprise |
|---|---|---|---|
| EPS (diluted) | $-2.10 | $-1.97 | +6.1% |
| Revenue | — | — | — |
Verdict reaction
How the verdict moved around this report
Verdict comparison pending — no verdict snapshot has been recorded for PCVX since this report yet.
Healthcare context
PCVX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $8.64B
- P/E (fwd)
- -8.0
- 52-week range
- $29.87–$65.00
- Off 52-week high
- 10.7%
- RSI (14)
- 57
- Volume vs avg
- 0.68×
- Engine score
- 5.6/10
Live context at TrendMatrix’s latest engine read — updates after the report date; not frozen to it.